Phase II Evaluation of Dolastatin-10 in Patients With Hormone Refractory Prostate Cancer
OBJECTIVES: I. Determine the objective response rate in patients with hormone refractory
prostate cancer treated with dolastatin 10. II. Determine the toxicity of this regimen in
this patient population.
OUTLINE: Patients receive dolastatin 10 IV bolus every 3 weeks. Treatment continues for a
minimum of 2 courses in the absence of unacceptable toxicity or disease progression.
PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study.
Primary Purpose: Treatment
Maha Hadi A. Hussain, MD
Barbara Ann Karmanos Cancer Institute
United States: Federal Government
|University of Colorado Cancer Center||Denver, Colorado 80262|
|Barbara Ann Karmanos Cancer Institute||Detroit, Michigan 48201|
|Fox Chase Cancer Center||Philadelphia, Pennsylvania 19111|